PABPC1
Basic information
Region (hg38): 8:100685816-100722809
Previous symbols: [ "PAB1", "PABPC2" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PABPC1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 2 | |||||
missense | 5 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | 2 | |||
non coding | 1 | |||||
Total | 0 | 0 | 5 | 1 | 2 |
Variants in PABPC1
This is a list of pathogenic ClinVar variants found in the PABPC1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
8-100703359-T-TTTTAAACAGTTGGAACACCAGTGG | CIC-rearranged sarcoma | not provided (-) | ||
8-100704305-G-A | not specified | Uncertain significance (Dec 21, 2022) | ||
8-100704309-G-C | not specified | Uncertain significance (Jul 25, 2023) | ||
8-100704316-G-A | Likely benign (Jan 01, 2023) | |||
8-100705029-G-A | not specified | Uncertain significance (Jul 20, 2021) | ||
8-100705064-C-T | Benign (Jul 31, 2018) | |||
8-100705591-A-G | Pulmonary artery atresia | Pathogenic (-) | ||
8-100706731-C-T | not specified | Uncertain significance (Jun 13, 2022) | ||
8-100706758-C-T | not specified | Uncertain significance (Nov 30, 2021) | ||
8-100709179-T-C | Benign (Jul 02, 2018) | |||
8-100709528-A-C | PABPC1-related condition | Likely benign (Sep 16, 2024) | ||
8-100709642-G-A | PABPC1-related condition | Likely benign (Sep 16, 2024) | ||
8-100712361-C-T | not specified | Uncertain significance (Apr 24, 2024) | ||
8-100712378-G-A | EBV-positive nodal T- and NK-cell lymphoma | Likely benign (-) | ||
8-100712395-C-CA | EBV-positive nodal T- and NK-cell lymphoma | Likely benign (-) | ||
8-100712397-CTT-C | EBV-positive nodal T- and NK-cell lymphoma | Likely benign (-) | ||
8-100712798-C-CA | Benign (Aug 08, 2018) | |||
8-100715538-T-C | EBV-positive nodal T- and NK-cell lymphoma | Likely benign (-) | ||
8-100717892-G-A | Benign/Likely benign (Mar 01, 2022) | |||
8-100718107-C-A | Teratoma | Uncertain significance (Jan 01, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PABPC1 | protein_coding | protein_coding | ENST00000318607 | 14 | 36994 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.996 | 0.00399 | 124412 | 0 | 1333 | 125745 | 0.00531 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.49 | 127 | 370 | 0.343 | 0.0000201 | 4130 |
Missense in Polyphen | 12 | 102.29 | 0.11731 | 1255 | ||
Synonymous | -0.279 | 118 | 114 | 1.03 | 0.00000539 | 1210 |
Loss of Function | 4.76 | 4 | 33.9 | 0.118 | 0.00000190 | 369 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0147 | 0.0135 |
Ashkenazi Jewish | 0.00533 | 0.00447 |
East Asian | 0.00560 | 0.00490 |
Finnish | 0.00202 | 0.00185 |
European (Non-Finnish) | 0.00645 | 0.00554 |
Middle Eastern | 0.00560 | 0.00490 |
South Asian | 0.00807 | 0.00682 |
Other | 0.00358 | 0.00310 |
dbNSFP
Source:
- Function
- FUNCTION: Binds the poly(A) tail of mRNA, including that of its own transcript. May be involved in cytoplasmic regulatory processes of mRNA metabolism such as pre-mRNA splicing. Its function in translational initiation regulation can either be enhanced by PAIP1 or repressed by PAIP2. Can probably bind to cytoplasmic RNA sequences other than poly(A) in vivo. Involved in translationally coupled mRNA turnover. Implicated with other RNA- binding proteins in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA mediated by the major coding- region determinant of instability (mCRD) domain. Involved in regulation of nonsense-mediated decay (NMD) of mRNAs containing premature stop codons; for the recognition of premature termination codons (PTC) and initiation of NMD a competitive interaction between UPF1 and PABPC1 with the ribosome-bound release factors is proposed. By binding to long poly(A) tails, may protect them from uridylation by ZCCHC6/ZCCHC11 and hence contribute to mRNA stability (PubMed:25480299). Positively regulates the replication of dengue virus (DENV) (PubMed:26735137). {ECO:0000269|PubMed:11051545, ECO:0000269|PubMed:17212783, ECO:0000269|PubMed:18447585, ECO:0000269|PubMed:20573744, ECO:0000269|PubMed:25480299, ECO:0000269|PubMed:26735137}.;
- Pathway
- RNA degradation - Homo sapiens (human);mRNA surveillance pathway - Homo sapiens (human);RNA transport - Homo sapiens (human);Translation Factors;Endoderm Differentiation;regulation of eif-4e and p70s6 kinase;skeletal muscle hypertrophy is regulated via akt-mtor pathway;Translation initiation complex formation;Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S;Eukaryotic Translation Initiation;Translation;Metabolism of proteins;AUF1 (hnRNP D0) binds and destabilizes mRNA;Metabolism of RNA;Nonsense-Mediated Decay (NMD);Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC);Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC);L13a-mediated translational silencing of Ceruloplasmin expression;Regulation of mRNA stability by proteins that bind AU-rich elements;Cap-dependent Translation Initiation;Deadenylation of mRNA;Deadenylation-dependent mRNA decay
(Consensus)
Recessive Scores
- pRec
- 0.453
Intolerance Scores
- loftool
- rvis_EVS
- -0.38
- rvis_percentile_EVS
- 27.42
Haploinsufficiency Scores
- pHI
- 0.499
- hipred
- Y
- hipred_score
- 0.681
- ghis
- 0.624
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.539
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | High | Medium | High |
Cancer | High | Medium | High |
Mouse Genome Informatics
- Gene name
- Pabpc1
- Phenotype
Zebrafish Information Network
- Gene name
- pabpc1a
- Affected structure
- pigment cell
- Phenotype tag
- abnormal
- Phenotype quality
- quality
Gene ontology
- Biological process
- nuclear-transcribed mRNA catabolic process, nonsense-mediated decay;mRNA splicing, via spliceosome;mRNA polyadenylation;translational initiation;gene silencing by RNA;regulation of mRNA stability;positive regulation of viral genome replication;positive regulation of translation;mRNA stabilization;positive regulation of nuclear-transcribed mRNA poly(A) tail shortening;positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay;negative regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay
- Cellular component
- nucleus;cytoplasm;cytosol;focal adhesion;cytoplasmic stress granule;membrane;cytoplasmic ribonucleoprotein granule;extracellular exosome;catalytic step 2 spliceosome;ribonucleoprotein complex
- Molecular function
- RNA binding;mRNA 3'-UTR binding;protein binding;protein C-terminus binding;poly(A) binding;poly(U) RNA binding;translation activator activity